RayzeBio, Inc. Common Stock
RayzeBio, Inc. Common Stock (RYZB) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
ryzb · pe ratio · data through Dec 31, 2022
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for RayzeBio, Inc. Common Stock (RYZB) measures how much investors pay for each dollar of the company's trailing earnings. RYZB's current PE ratio of N/A is calculated by dividing its stock price of $62.49 by its TTM earnings per share of -$1.75.
Source: FMP · /ratios-ttm · /analyst-estimates · 2022-12-31
PE Ratio History
2020 – 2022 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
RayzeBio, Inc. Common StockYou RYZB | $3.8B | N/A | — | -$1.75 |
 Alpine Immune Sciences, Inc. ALPN | $4.5B | N/A | — | -$0.64 |
 CymaBay Therapeutics, Inc. CBAY | $3.7B | N/A | — | -$0.99 |
 Chinook Therapeutics, Inc. KDNY | $2.7B | N/A | — | -$2.87 |
 MorphoSys AG MOR | $2.9B | N/A | — | -$1.38 |
 Morphic Holding, Inc. MORF | $2.9B | N/A | — | -$3.59 |
 Mirati Therapeutics, Inc. MRTX | $4.1B | N/A | — | -$13.18 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2022-12-31Latest FY2022 | — | $-1.75 | — | |
2021-12-31 FY2021 | — | $-0.73 | — | |
2020-12-31 FY2020 | — | $-0.17 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for RayzeBio, Inc. Common Stock (RYZB) measures how much investors pay for each dollar of the company's trailing earnings. RYZB's current PE ratio of N/A is calculated by dividing its stock price of $62.49 by its TTM earnings per share of -$1.75.
Frequently asked questions
RYZB pe ratio · 6 questionsRYZB's current PE ratio is N/A as of 2026-06-08, based on a stock price of $62.49 and TTM EPS of -$1.75. Data sourced from Financial Modeling Prep via RYZB's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · RayzeBio, Inc. Common Stock SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08